Objective: The objective was to determine the effectiveness of real-time continuous glucose monitoring (CGM) in adults ≥ 60 years of age with type 1 (T1D) or type 2 (T2D) diabetes using multiple daily insulin injections (MDI).
Numerous studies have demonstrated that persistent use of real-time continuous glucose monitoring (CGM) improves glycemic control [1] [2] [3] [4] [5] [6] and quality of life 7 in individuals with type 1 diabetes (T1D) using continuous subcutaneous insulin infusion (CSII) and multiple daily insulin injection (MDI) therapy. The benefits of CGM use have also been reported in individuals with T2D who are managed with or without intensive insulin treatment. [8] [9] [10] [11] [12] [13] [14] The American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE), American Diabetes Association, Endocrine Society and Joslin Diabetes Center recommend that CGM should be made available to individuals with T1D, T2D individuals treated with intensive insulin regimens, and all patients with diabetes who are at risk for hypoglycemia and/or have hypoglycemia unawareness. [15] [16] [17] [18] It is well recognized that the risk of severe or fatal hypoglycemia increases exponentially with age in elderly individuals with diabetes who are treated with insulinotropic medications. [19] [20] [21] Studies have shown that elderly T1D adults have higher rates of hypoglycemia and greater frequency of hypoglycemia unawareness than younger adults with T1D. 22, 23 A recent observational study by DuBose and colleagues found that approximately one half of older adults with long-standing T1D spend at least 90 minutes per day <70 mg/dL, with a quarter at <70 mg/dL for at least 2.5 hours per day.
Evidence from a small retrospective study suggests that use of CGM by older T1D adults may reduce the frequency of severe hypoglycemic episodes and improve overall glycemic control; 25 however, there are limited data regarding use of stand-alone CGM in older individuals with diabetes using multiple daily injections. The potential to decrease HbA1c and reduce rates of severe hypoglycemia in this population has both significant clinical and financial implications.
We conducted a 24-week randomized multicenter clinical trial (DIAMOND study) that evaluated the effect of CGM on glycemic control in MDI-treated T1D and T2D adults with elevated HbA1c levels. Results from analysis of the T1D and T2D study participants across a large age range (26-79 years) showed that use of CGM compared with self-monitoring of blood glucose (SMBG) resulted in a greater decrease in HbA1c level during 24 weeks. 26, 27 In this report, we present findings from a subset analysis of the full DIAMOND study population that assessed the effectiveness of CGM use in MDI-treated T1D and T2D individuals ≥60 years of age
Methods
The DIAMOND trial was conducted at 29 endocrinology practices across North America, 27 of which enrolled older adults (21 community-based and 6 academic). The study is listed on www.clinicaltrials.gov, under identifier NCT02282397. The protocol and Health Insurance Portability and Accountability Act (HIPAA)-compliant informed consent forms were approved by a central and multiple local institutional review boards. Details of the protocol have been published. 26 Key aspects of the protocol are summarized herein.
Study Participants
Written informed consent was obtained from each participant. Major eligibility criteria for this analysis included age ≥60 years, diagnosis of T1D or T2D being treated with multiple daily injections of insulin for at least one year, central laboratory measured HbA1c 7.5% to 10.0%, stable diabetes medication regimen and weight over the prior 3 months, selfreported blood glucose meter testing averaging 2 or more times per day for T2D and 3 or more for T1D, and estimated glomerular filtration rate ≥45. Major exclusion criteria were use of real-time CGM within 3 months of screening and any medical condition(s) that would make it inappropriate or unsafe to target an HbA1c of <7.0%. This determination was made by investigators.
Study Design
Prior to randomization to either CGM or SMBG (Control), each participant used a CGM device for 2 weeks that recorded glucose concentrations not visible to the participant (referred to as a "blinded" CGM). Participants in both groups were provided with a Contour Next USB meter and test strips (Ascensia Diabetes Care, Parsippany, NJ, USA). Participants in the CGM group were provided with a Dexcom™ G4 Platinum CGM System® with an enhanced algorithm (software 505) (Dexcom, Inc, San Diego, CA), which measures glucose concentrations from interstitial fluid in the range of 40 to 400 mg/dL every 5 minutes. General guidelines were provided to participants about using CGM, and individualized recommendations were made by their clinician about individual goals and incorporating CGM trend information into their diabetes management. CGM was used adjunctive to blood glucose monitoring, according to the US Food and Drug Administration (FDA) labeling at the time the study was conducted. The Control group was asked to perform home blood glucose monitoring at least 4 times daily. Specific insulin adjustments were not prescriptive in the protocol for either group but instead were at the discretion of treating clinicians at the clinical sites.
Follow-up visits for both treatment groups occurred after 4, 12, and 24 weeks. The CGM group had an additional visit one week after randomization to troubleshoot potential use issues. The Control group had 2 additional visits 1 week prior to the 12 and 24 week visits to initiate blinded CGM use for 1 week. Phone contacts for both groups occurred 2 weeks and 3 weeks after randomization.
HbA1c was measured at baseline, 12 weeks, and 24 weeks at the Northwest Lipid Research Laboratories, University of Washington, Seattle, WA using the Diabetes Control and Complications Trial standardized analyzer (TOSOH, Biosciences, Inc, South San Francisco, CA). Satisfaction with CGM was assessed by completion of the CGM Satisfaction Scale by the CGM group at 24 weeks. The survey consists of 44 items indicating the degree of agreement or disagreement on a 1-5 Likert scale, with 2 subscales referred to as "benefits" and "hassles." 28 Numeracy was assessed using the Diabetes Numeracy Test-15 (DNT-5), a 5-item questionnaire that investigates numeracy skills in individuals with diabetes. 29 Severe hypoglycemia (SH) was defined as an event that required assistance from another person to administer carbohydrates or other resuscitative action and diabetic ketoacidosis was defined as an event involving all of the following: symptoms such as polyuria, polydipsia, nausea, or vomiting; serum ketones >1.5 mmol/L or large/moderate urine ketones; either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15; and treatment provided in a health care facility.
Statistical Methods
The primary outcome was change in the central-laboratory measured HbA1c from baseline to 24 weeks. The primary analysis was a treatment group comparison of the change in HbA1c from baseline to 24 weeks in an analysis of covariance (ANCOVA) model, adjusted for baseline HbA1c and clinical site as a random effect. Confounding was assessed by repeating the analysis including potential confounding variables as covariates.
CGM data obtained in conjunction with the 12-week and 24-week visits (blinded use in the Control group and unblinded use in the CGM group for approximately 7 days each time) were used to determine the amount of time per day the glucose concentration was hypoglycemic (<60 mg/ dL), hyperglycemic (>250 mg/dL), and in the target range of 70 to 180 mg/dL at each visit. Glucose variability was assessed by computing the coefficient of variation (CV). Treatment group comparisons were made on the pooled data from 12 and 24 weeks with ANCOVA models based on ranks using van der Waerden scores if the metric was skewed, adjusted for the corresponding baseline value, baseline HbA1c, and clinical site as a random effect. Frequency of blood glucose self-monitoring was based on meter downloads and compared between groups using ANCOVA, adjusted for the baseline frequency and clinical site as a random effect. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). All P values are 2-sided.
Results
In this analysis, 116 T1D (n = 34) and T2D (n = 82) participants with mean age of 67 ± 5 years were randomly assigned to the CGM group (n = 63) or Control group (n = 53). Median diabetes duration was 21 (14, 30) years and mean baseline HbA1c was 8.5 ± 0.6%. Participant characteristics according to treatment group are presented in Table 1 . The groups were well-balanced among education levels and diabetes numeracy. The 24-week primary study outcome visit was completed by 61 (97%) of the CGM group and 53 (100%) of the Control group (Figure 1 ).
Change in HbA1c and other CGM metrics
Mean HbA1c, which at baseline was 8.4 ± 0.6% in the CGM group and 8.6 ± 0.7% in the Control group, decreased to 7.5 ± 0.7% and 8.0 ± 0.7%, respectively at 12 weeks with an adjusted difference in mean change in HbA1c of −0.4 ±0.1% (P < .001). At 24 weeks, HbA1c reduction from baseline was greater in the CGM group than Control group (−0.9 ± 0.7% vs −0.5 ± 0.7%) with an adjusted difference in mean change of −0.4 ± 0.1% (P < .001). For each treatment group, baseline and 24-week HbA1c values for each participant relative to American Diabetes Association targets are shown in Figure 2A , and the cumulative distribution of the 24-week HbA1c values is shown in Figure 2B .
Significant between-group differences in improvements in CGM-measured mean glucose, glycemic variation (CV) and in the average time within glucose range (70-180 mg/dL) and in hyperglycemia (>250 mg/dL) at 24 weeks were observed; however, there was minimal hypoglycemia at baseline in both the CGM and Control groups (median time <60 mg/dL was 10 vs 8 minutes/day, respectively), which affected the ability to detect a difference in hypoglycemia (Table 2) .
Glucose Monitoring
Among the 61 CGM participants completing the trial, mean CGM use was 6.9 ± 0.2 days/week in month one (weeks 1-4); and 6.8 ± 1.1 in month 6 (weeks 21-24); 97% used CGM ≥ 6 days/week in month 6. The mean reduction in the number of daily blood glucose tests from baseline to week 24 was significantly greater for the CGM group compared with the Control group (−1.2 ± 1.6 vs −0.2 ± 1.4, P = .001).
CGM Satisfaction
In the CGM group, satisfaction with use of CGM was high as indicated by the mean score of 4.2 ± 0.4 on the CGM Satisfaction Survey (possible score range 1 to 5), with mean scores of 4.3 ± 0.5 on the Benefits subscale and 1.8 ± 0.5 on the Hassles subscale, indicating that perceived benefits were high while perceived hassles were few (Table 3) .
Adverse Events
There were no SH or diabetic ketoacidosis events in either group.
Discussion
In this analysis of T1D and T2D individuals ≥60 years old treated with MDI therapy, improvement in HbA1c at 24 weeks was significantly greater in participants using realtime CGM than in the Control group using a blood glucose meter alone for glucose monitoring. The greater HbA1c improvement in the CGM group was reflected in significantly reduced time in CGM-measured time above 250 mg/dL (P = .006) and less glycemic variability (P = .02). Although no cases of SH occurred in either group, the trial's ability to assess the benefit of CGM on reducing hypoglycemia was limited due to the minimal amount of hypoglycemia recorded at baseline. Nevertheless, the minimal hypoglycemia among CGM participants throughout the study is notable given significant improvement in HbA1c and glycemic variability despite the reduction in daily blood glucose testing observed relative to the Control group. One surprising finding from the study was the sustained use of CGM. In view of the limited number of prior studies of CGM in older individuals with diabetes, it was unknown if seniors would demonstrate sustained daily use of CGM over 6 months. Among the 61 in the CGM group completing the trial, 97% used CGM ≥6 days/week in month 6. This persistence in CGM use is also reflected in participants' responses to the CGM Satisfaction Survey at the end of the trial, which indicated very high satisfaction with CGM. This likely contributed to the very high frequency of use, particularly since the protocol had only one visit after week 4 and no scheduled visits or phone contacts between 12 weeks and 24 weeks.
The strengths of this randomized trial included very high treatment adherence and participant retention, a protocol and study processes that can be replicated in realworld clinical practice and central-laboratory measurement of HbA1c. With participation in the trial by both community-based and academic sites and broad eligibility criteria, the trial results should be generalizable to most patients with MDI-treated T1D and T2D who are ≥60 years with HbA1c 7.5% to 9.9%. The study population also was well-matched with the current insulin-using Medicare population. Data from the Centers for Medicare & Medicaid Services show that approximately 65.9% of beneficiaries are treated with prandial insulin (including premixed insulins) with or without basal insulin. 31 Moreover, our findings are consistent with other studies. A recent retrospective study by Argento and colleague found that use of CGM in older diabetes patients resulted in significant and durable improvement in HbA1c (−0.5%) and reductions in both the percentage of patients reporting severe hypoglycemic (SH) episodes and the frequency of SH per patient despite a lower baseline HbA1c (7.6%) 25 than observed in our cohorts (8.5%). Polonsky and colleagues recently surveyed 285 elderly T1D (n = 260) and T2D (n = 25) individuals who were either currently using CGM (n = 210) or hoped to acquire a CGM device for their self-management. 32 Current users reported significantly fewer moderate and severe hypoglycemic episodes over the previous 6 months than nonusers as well as significantly greater reductions in hypoglycemic events requiring the assistance of another, emergency room visits and paramedic visits to the home. In other studies, CGM users also reported having a significantly higher quality of life than nonusers. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 26 As discussed earlier, hypoglycemia is particularly common in older individuals with diabetes. [22] [23] [24] Although current guidelines suggest higher HbA1c goals for this population, 16 less stringent glycemic control will do little to prevent severe hypoglycemia due to the high prevalence (45%) of hypoglycemia unawareness among these individuals. 23 A potential limitation is that this study did not address the question of whether CGM would reduce severe hypoglycemia events in the vulnerable population. The DIAMOND study was designed and powered to investigate whether CGM use would reduce HbA1c.
Conclusions
This randomized trial demonstrates that real-time CGM can be beneficial for elderly adults with T1D and T2D treated with basal-bolus insulin therapy, as has been shown in prior studies in younger adults with diabetes. A high percentage of the study participants used CGM on a daily or near-daily basis over 6 months with a limited number of visits and phone contacts (none after 3 months). CGM use was associated with a high degree of patient satisfaction, reduction in HbA1c, hyperglycemia and glycemic variability and an increase in time in glucose range. Given these significant benefits, CGM should be considered for older adults with diabetes using MDI. . One participant did not complete the questionnaire at the conclusion of the study. Responses were missing from 1 participant for items 3, 5, 6, 12, 26, 29, 37 , and 39 and missing from 2 participants for item 15. Items with a ► symbol are positively worded (agreeing corresponds to more satisfaction) and those without the symbol are negatively worded (agreeing corresponds to less satisfaction). To calculate the mean value for each item and the overall mean value, the scores for the positively worded items were reversed so that a higher score always corresponds to greater satisfaction. For example, a value of 5 corresponds to "agree strongly" with a positively worded item, or "disagree strongly" with a negatively worded item. To calculate the subscale mean values, scores for all questions were reversed so that a higher score on the Benefits subscale denotes greater satisfaction and a higher score on the Hassles subscale denotes less satisfaction. 
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